

**ASX Announcement 31 January 2025
Optiscan Imaging Ltd (ASX:OIL)**

OPTISCAN RECEIVES \$1.775m R&D TAX REFUND

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the 'Company'), a leader in medical imaging using confocal laser endomicroscopy, is pleased to advise that the Company has received its research and development (R&D) tax refund for the 2024 financial year (FY24) amounting to \$1,775,733. The refund received is part of the Australian Federal Government's R&D tax incentive program that enables companies engaged in appropriate and eligible R&D activities to claim a refundable tax offset of up to 43.5%.

The amount received for FY24 of \$1,775,733 is significantly higher than last year's \$672,320 due to the successful outcome of the Advance and Overseas Finding application, that allows companies to claim eligible overseas R&D costs through the Australian Government's R&D tax incentive program.

Optiscan's Chief Executive Officer and Managing Director, Dr. Camile Farah, commented:

"We appreciate the Australian Government's R&D tax incentive program, which recognises the significant research and development efforts involved in creating innovative medical technology such as that at Optiscan. Our technology has the potential to deliver substantial positive outcomes to the medical industry, the nation and ultimately to patients. The increased refund received this year will be utilised to support our ongoing R&D projects which have made significant progress, allowing us to bring Optiscan's advanced technology to a wider market on time."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network


Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.



Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.